Selfotel in Acute Ischemic Stroke
- 1 February 2000
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 31 (2), 347-354
- https://doi.org/10.1161/01.str.31.2.347
Abstract
Background and Purpose —Based on neuroprotective efficacy in animal models, we evaluated the N -methyl d -aspartate antagonist Selfotel in patients with ischemic stroke, after doses up to 1.5 mg/kg were shown to be safe in phase 1 and phase 2a studies. Methods —Two pivotal phase 3 ischemic stroke trials tested the hypothesis, by double-blind, randomized, placebo-controlled parallel design, that a single intravenous 1.5 mg/kg dose of Selfotel, administered within 6 hours of stroke onset, would improve functional outcome at 90 days, defined as the proportion of patients achieving a Barthel Index score of ≥60. The trials were performed in patients aged 40 to 85 years with acute ischemic hemispheric stroke and a motor deficit. Results —The 2 trials were suspended on advice of the independent Data Safety Monitoring Board because of an imbalance in mortality after a total enrollment of 567 patients. The groups were well matched for initial stroke severity and time from stroke onset to therapy. There was no difference in the 90-day mortality rate, with 62 deaths (22%) in the Selfotel group and 49 (17%) in the placebo-treated group (RR=1.3; 95% CI 0.92 to 1.83; P =0.15). However, early mortality was higher in the Selfotel-treated patients (day 30: 54 of 280 versus 37 of 286; P =0.05). In patients with severe stroke, mortality imbalance was significant throughout the trial ( P =0.05). Conclusions —Selfotel was not an effective treatment for acute ischemic stroke. Furthermore, a trend toward increased mortality, particularly within the first 30 days and in patients with severe stroke, suggests that the drug might have a neurotoxic effect in brain ischemia.This publication has 14 references indexed in Scilit:
- Tissue Plasminogen Activator for Acute Ischemic StrokeThe New England Journal of Medicine, 1995
- Why do all drugs work in animals but none in stroke patients? 2 Neuroprotective therapyJournal of Internal Medicine, 1995
- White matter changes and ventricular enlargement on magnetic resonance imaging: Comparison between normal elderly subjects and patients with cerebrovascular disordersJournal of Stroke and Cerebrovascular Diseases, 1994
- Viability thresholds and the penumbra of focal ischemiaAnnals of Neurology, 1994
- The Current Status of Neuronal Protective Therapy: Why Have All Neuronal Protective Drugs Worked in Animals but None So Far in Stroke Patients?Cerebrovascular Diseases, 1994
- Characterization of the Cerebroprotective Efficacy of the Competitive NMDA Receptor Antagonist CGP40116 in a Rat Model of Focal Cerebral Ischemia: An in vivo Magnetic Resonance Imaging StudyJournal of Cerebral Blood Flow & Metabolism, 1993
- Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion‐weighted MRINeurology, 1993
- The Effects of a Competitive NMDA Receptor Antagonist (CGS-19755) on Cerebral Blood Flow and pH in Focal IschemiaJournal of Cerebral Blood Flow & Metabolism, 1991
- The pharmacotherapy of focal cortical ischaemia in the mouseBrain Research, 1990
- N‐Methyl‐D‐Aspartate antagonist reduces stroke size and regional glucose metabolismAnnals of Neurology, 1990